Effect of primary anthracycline-based chemotherapy on disseminated tumor cells in locally advanced breast cancer

被引:0
|
作者
Jäger, C [1 ]
Kafka, A [1 ]
Bossert, S [1 ]
Grundmann, R [1 ]
Windisch, J [1 ]
Kreienberg, R [1 ]
Heilmann, V [1 ]
机构
[1] Univ Ulm, Dept Obstet & Gynecol, D-89075 Ulm, Germany
关键词
breast cancer; disseminated tumor cells; anthracycline-based; chemotherapy;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: The leading cause of death from epithelial cancer is metastatic tumor relapse due to early dissemination of tumor cells. In this study we investigated the elimination rate of disseminated tumor cells in bone marrow and the clinical response under primary chemotherapy in locally advanced breast cancer. Patients and Methods: Thirty patients underwent primary anthracycline-containing chemotherapy for breast cancer. For immunocytochemical tumor cell detection in bone marrow, the monoclonal antibody 5D3 was used. Results: At time of diagnosis, 10/30 (33%) patients had cytokeratin-positive tumor cells in bone marrow. After primary and chemotherapy, 8/30 (27%) patients still tested positive. Clinical complete response (cCR) was observed in 5/30 (17%) patients partial response (cPR) in 12/30 (40%) patients, resulting in an overall rate of clinical response to primary chemotherapy in 57%. Conclusion: Primary chemotherapy in breast cancer is effective regarding the reduction of tumor size but seems incapable of reducing the burden of disseminated tumor cells in bone marrow.
引用
收藏
页码:3209 / 3214
页数:6
相关论文
共 50 条
  • [21] The effect of anthracycline-based (epirubicin) adjuvant chemotherapy on plasma TAFI and PAI-1 levels in operable breast cancer
    Demirkan, B
    Özcan, MA
    Alacacioglu, A
    Yüksel, F
    Ündar, B
    Alakavuklar, M
    CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 2006, 12 (01) : 9 - 14
  • [22] Neutrophil count is not associated with infection episodes in breast cancer patients treated with anthracycline-based chemotherapy
    Mendonca, M. A. O.
    Pereira, A. H. M.
    Silva, S. R.
    Mardegan, M. C.
    Murta, E. F. C.
    Tavares-Murta, B. M.
    EUROPEAN JOURNAL OF CANCER CARE, 2009, 18 (02) : 184 - 190
  • [23] Oxidative and antioxidative status after anthracycline-based chemotherapy in breast cancer patients
    Alacacioglu, A.
    Kebapcilar, L.
    Pamuk, B. Onder
    Sop, G.
    Kucukiravul, C.
    Bozkaya, G.
    Yuksel, A.
    Alacacioglu, I.
    Sari, I.
    JOURNAL OF BUON, 2013, 18 (03): : 614 - 618
  • [24] Correlation between complete response to anthracycline-based chemotherapy and topoisomerase II-α gene amplification and protein overexpression in locally advanced/metastatic breast cancer
    Cardoso, F
    Durbecq, V
    Larsimont, D
    Paesmans, M
    Leroy, JY
    Rouas, G
    Sotiriou, C
    Renard, N
    Richard, V
    Piccart, MJ
    Di Leo, A
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2004, 24 (01) : 201 - 209
  • [25] neutrophil-lymphocyte ratio (NLR) with the anthracycline-based neoadjuvant chemotherapy (NAC) clinical response in locally advanced breast cancer (LABC) in young women
    Winantyo, Vania Idelia
    Tanggo, Vidi Vianney Chrisana Magrit
    Ali, Iskandar
    BALI MEDICAL JOURNAL, 2022, 11 (02) : 602 - 608
  • [26] Dose and dose intensity effect of adjuvant anthracycline-based chemotherapy in early breast cancer -: A retrospective analysis
    Amador, ML
    Jimeno, A
    Hitt, R
    Cortés-Funes, H
    Colomer, R
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2004, 27 (03): : 269 - 273
  • [27] Simultaneous detection of circulating and disseminated tumor cells in primary breast cancer patients following neoadjuvant chemotherapy
    Walter, Vincent P.
    Taran, Florin-Andrei
    Wallwiener, Markus
    Hahn, Markus
    Brucker, Sara Y.
    Hartkopf, Andreas D.
    ARCHIVES OF GYNECOLOGY AND OBSTETRICS, 2018, 297 (03) : 785 - 790
  • [28] Right heart function deteriorates in breast cancer patients undergoing anthracycline-based chemotherapy
    Boczar K.E.
    Aseyev O.
    Sulpher J.
    Johnson C.
    Burwash I.G.
    Turek M.
    Dent S.
    Dwivedi G.
    Echo Research & Practice, 2016, 3 (3) : 79 - 84
  • [29] Overexpression of ANLN contributed to poor prognosis of anthracycline-based chemotherapy in breast cancer patients
    Wang, Zhan
    Chen, Juan
    Zhong, Mei-Zuo
    Huang, Juan
    Hu, Yuan-Ping
    Feng, De-Yun
    Zhou, Zhi-Jiao
    Luo, Xiao
    Liu, Zhao-Qian
    Jiang, Wu-Zhong
    Zhou, Wei-Bing
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2017, 79 (03) : 535 - 543
  • [30] FKBP12 is a predictive biomarker for efficacy of anthracycline-based chemotherapy in breast cancer
    Xing, Mingyou
    Wang, Jun
    Yang, Qin
    Wang, Yu
    Li, Jiansha
    Xiong, Jing
    Zhou, Sheng
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2019, 84 (04) : 861 - 872